Online inquiry

IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5816MR)

This product GTTS-WQ5816MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD40 gene. The antibody can be applied in Kidney transplant rejection, Psoriasis, Myasthenia Gravis (MG) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001250.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 958
UniProt ID P25942
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ5816MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9813MR IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA JS004
GTTS-WQ997MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ9705MR IVTScrip™ mRNA-Anti-KLRK1, JNJ-64304500(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64304500
GTTS-WQ10118MR IVTScrip™ mRNA-Anti-LAG3, LAG-525(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LAG-525
GTTS-WQ11373MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ8139MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HH1
GTTS-WQ9092MR IVTScrip™ mRNA-Anti-CD3E&PMEL, IMCgp100(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA IMCgp100
GTTS-WQ15392MR IVTScrip™ mRNA-Anti-CD37, TRU-016(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA TRU-016
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW